Purple Biotech Ltd. (PPBT) - Margin operasi

Lambang korporat lan logo Purple Biotech (PPBT)

Purple Biotech centers in Israel are developing treatments to combat resistance in solid tumors. The operating profit margin reflects efficiency dynamics, with the metric currently at 0.00. While the scientific staff of PhD specialists is creating targeted therapies, high R&D costs and clinical trial risks are forcing the company to raise additional capital, which may lead to share dilution.

PPBT - Tingkat bathi operasi purple-biotech.com ing rentang 04.07.2022 - 19.11.2026

PPBT (purple-biotech.com): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:
Analisis fundamental perusahaan:Purple Biotech Ltd.
Produk dadi Purple Biotech

Operating margin reflects the efficiency of profit generation from core business processes relative to revenue, demonstrating the asset's ability to convert sales into operating income before accounting for financial obligations. An analysis of the calculated operating margin allows for an assessment of Purple Biotech (PPBT) resilience to oncology drug development costs, where high volatility of this indicator signals a critical balance between R&D expenses and the risk of capital dilution.

Pesaing langsung

Rentabilitas operasi BeiGene Ltd|Halozyme Therapeutics - Margin bathi operasi|Margin dodolan operasi RVMD (Revolution Medicines Corp)|Rasio bathi operasi AAPG|Rentabilitas operasi CG Oncology Therapeutics CGON|Tingkat bathi operasi URGN|BCAX: Margin dodolan operasi|PSNL: Rentabilitas operasi|Erasca (ERAS) - Rentabilitas operasi|DCTH - Rentabilitas kegiatan operasi|YMAB (Y-mAbs Corp) - Margin operasi|Margin dodolan operasi Aura Biosciences (AURA)|Rentabilitas operasi Candel Therapeutics Inc. (CADL)|Margin dodolan operasi Accuray, Inc. ARAY|Rentabilitas operasi sellaslifesciences.com SLS|Tingkat bathi operasi ACTU|CTOR - Rentabilitas operasi|Rentabilitas kegiatan operasi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Rentabilitas operasi|FATE: Rasio bathi operasi|WHWK (Aadi Bioscience, Inc.) - Margin operasi|TCRX (TScan Therapeutics) - Rasio bathi operasi|Rentabilitas operasi Champions Oncology (CSBR)|Rentabilitas kegiatan operasi XBiotech USA|Rentabilitas operasi CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Rentabilitas dodolan operasi|RADX - Rentabilitas operasi|ARTV - Margin operasi|Adlai Nortye Ltd (ANL) - Rentabilitas operasi|Veru Pharma - Tingkat bathi operasi|Rentabilitas operasi Tempest Therapeutics Corp|Rentabilitas dodolan miturut bathi operasi XLO (Xilio Therapeutics, Inc.)|Margin operasi RENB|MURA (Mural Oncology) - Tingkat bathi operasi|Margin operasi KAPA (Kairos Pharma Ltd)|OKUR: Rentabilitas dodolan miturut bathi operasi|GDTC: Margin dodolan operasi|CRIS - Margin operasi|APLM: Margin operasi|Rentabilitas dodolan operasi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Margin operasi|Margin operasi Genprex Inc.|Margin operasi CLDI|Margin dodolan operasi Sunshine Biopharma, Inc. SBFM|Margin operasi XBIO (Xenetic Biosciences)|Tingkat bathi operasi SLRX|AONC - Rentabilitas operasi|BGNE: Rentabilitas operasi|CKPT: Margin operasi|Elevation Oncology - Tingkat bathi operasi|ICAD (iCAD) - Margin operasi|IKNA: Tingkat bathi operasi|Rentabilitas operasi Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Tingkat bathi operasi|Rentabilitas operasi MorphoSys Corporation MOR|NAYA: Rentabilitas dodolan miturut bathi operasi|Ascentage Pharma Group International - Margin operasi